登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 截至本公告披露日，桂林三金药业股份有限公司（以下简称公司）及控股子公司实际担保余额为26,371 万元（含本次担保），占公司最近一期经审计净资产的8.76%。本次担保的被担保人为公司全资孙公司 白帆生物科技（上海）有限公司（以下简称白帆生物），资产负债率超过70%。公司及控股子公司、控 股孙公司未对合并报表外单位提供担保，也无逾期债务对应的担保余额、涉及诉讼的担保金额及因被判 决败诉而应承担的担保金额。敬请投资者充分关注担保风险。 一、担保情况概述 （一）本次担保进展情况 近日，白帆生物向厦门国际银行股份有限公司上海分行（以下简称厦门国际银行上海分行）申请了人民 币2,000万元的授信额度，公司与厦门国际银行上海分行签订了合同编号为"0905202601238429BZ-1"的 《保证合同》，公司同意为白帆生物在2026年1月23日到2028年4月23日期间内向厦门国际银行上海分行 在授信额度内申请提供的一系列债权提供连带责任保证担保。 （二）担保额度 ...

关于为孙公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 截至本公告披露日，桂林三金药业股份有限公司（以下简称公司）及控股子 公司实际担保余额为26,371万元（含本次担保），占公司最近一期经审计净资产 的8.76%。本次担保的被担保人为公司全资孙公司白帆生物科技（上海）有限公 司（以下简称白帆生物），资产负债率超过70%。公司及控股子公司、控股孙公 司未对合并报表外单位提供担保，也无逾期债务对应的担保余额、涉及诉讼的担 保金额及因被判决败诉而应承担的担保金额。敬请投资者充分关注担保风险。 一、担保情况概述 （一）本次担保进展情况 近日，白帆生物向厦门国际银行股份有限公司上海分行（以下简称厦门国际 银行上海分行）申请了人民币 2,000 万元的授信额度，公司与厦门国际银行上海 分行签订了合同编号为"0905202601238429BZ-1"的《保证合同》，公司同意为 白帆生物在 2026 年 1 月 23 日到 2028 年 4 月 23 日期间内向厦门国际银行上海分 行在授信额度内申请提供的一系列债权提供连带责任保证担保。 ...

证券日报网讯 2月13日，桂林三金在互动平台回答投资者提问时表示，截至2026年2月10日股东总户数 为19068户。 （文章来源：证券日报） ...

Group 1 - The core viewpoint of the news is the implementation of the "Traditional Chinese Medicine Industry High-Quality Development Implementation Plan (2026-2030)" by the Ministry of Industry and Information Technology and eight other departments, which emphasizes support for leading enterprises like Guilin Sanjin [1] - Guilin Sanjin has completed the revision and re-registration of its core traditional Chinese medicine products, aligning with new regulations and eliminating delisting risks [1] - The policy and the company's compliance dynamics highlight a trend towards industry standardization, which is expected to have a long-term positive impact on traditional Chinese medicine companies like Guilin Sanjin [1] Group 2 - Recently, Guilin Sanjin's stock price has shown narrow fluctuations, closing at 14.70 yuan on February 11, 2026, with a daily decline of 0.34% and a trading volume of 29.50 million yuan [2] - Over the past five days, the stock has increased by 0.68% with a volatility of 2.47%, while the main capital saw a net outflow of 1.76 million yuan on February 11, indicating stable overall liquidity [2] - Technical analysis shows the stock price is near the middle band of the Bollinger Bands at 14.57 yuan, with short-term support at 14.28 yuan and resistance at 14.86 yuan [2] Group 3 - The financial report for the first three quarters of 2025 indicates that the company's operating revenue is 1.462 billion yuan, a year-on-year decrease of 7.14%, while the net profit attributable to shareholders is 385 million yuan, a slight increase of 0.35% [3] - The increase in net profit is primarily due to cost control, with a maintained gross margin of 75.23% [3] - The net cash flow from operating activities has significantly increased by 84.63% to 432 million yuan, and the debt-to-asset ratio stands at 24.53%, indicating a robust financial structure [3] Group 4 - According to a report from Zhongyou Securities, the high-quality development plan for the traditional Chinese medicine industry will accelerate structural optimization, directly benefiting leading enterprises with brand and compliance advantages [4] - Some market analysts believe that Guilin Sanjin, as an established traditional Chinese medicine company, has a strong brand moat but exhibits low growth potential, necessitating attention to the expansion of second-tier products and the progress of innovative drugs [4] - Current institutional ratings are predominantly neutral, with a forecasted net profit decline of 9.76% for 2025, but a potential recovery in positive growth is expected in 2026 [4]

证券日报网讯2月5日，桂林三金（002275）在互动平台回答投资者提问时表示，公司主要中药品种的说 明书均已修订完善，并完成了再注册，该规定不会影响产品正常上市销售。 ...

证券日报网讯2月5日，桂林三金（002275）在互动平台回答投资者提问时表示，截至2026年1月30日股 东总户数为19225户。 ...

Group 1 - The core point of the article is that Guilin Sanjin has reported a total of 18,963 shareholders as of January 20, 2026 [2]

Group 1 - The company, Guilin Sanjin (002275), responded to investor inquiries on January 22, indicating that the company secretary is primarily responsible for information disclosure, investor relations management, organizing board and shareholder meetings, and compliance governance [1] - For specific details, the company advised to refer to the "Board Secretary Work System" document, which will be disclosed in December 2025 [1]

Group 1 - The company, Guilin Sanjin (002275.SZ), has no plans to acquire Guangxi Jinsangzi to strengthen its respiratory system drug portfolio [2] - An investor inquired about the potential acquisition on an investor interaction platform [2] - The company responded to the inquiry on January 22, indicating the absence of any acquisition plans [2]

Group 1 - The company, Guilin Sanjin, reported that as of January 9, 2026, the total number of shareholders is 19,196 [2]